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Deadly ConformationsÐProtein Review
Misfolding in Prion Disease
Arthur L. Horwich* and Jonathan S. Weissman² and progressive dementia, occurring after age 40, asso-
ciated, as in kuru, with plaques in the brain of affected*Department of Genetics
and Howard Hughes Medical Institute individuals (Gerstmann et al., 1936). Multiple affected
family members were observed, in a pattern indicatingYale University School of Medicine
New Haven, Connecticut 06510 autosomal-dominant inheritance. Similar genetic trans-
mission has also been observed for a rare condition²Department of Cellular and Molecular
Pharmacology more recently described, familial fatal insomnia (FFI),
exhibiting lethal insomnia and autonomic dysfunctionUniversity of California-San Francisco School
of Medicine associated with pathologic changes confined to nuclei
in the thalamus (e.g., Manetto et al., 1992). By contrast,San Francisco, California 94143
the more common condition, Creutzfeldt-Jakob disease
(CJD), usually occurs sporadically and presents with
dementia occurring after age 40, with pathology gener-
Novel infectious particles, termed prions, composed ally featuring spongiform degeneration (Figure 1 and see
largely and perhaps solely of a single protein, are the DeArmond and Prusiner, 1996, for review). While most
likely causative agents of a group of transmissible spon- CJD casesare sporadic inoccurrence, autosomal-domi-
giform encephalopathies that produce lethal decline of nant transmission accounts for z10% of cases. Hori-
cognitive and motor function. As if the notion of a trans- zontal transmission of CJD to chimpanzee was demon-
missible pathogenic protein is not jarring enough, evi- strated early (Gibbs et al., 1968), but particularly notable
dence indicates that the responsible protein arrives at have been cases of transmission between humans iatro-
a pathogenic state by misfolding from a normal form genically, through transplantation of infected corneas
that has ubiquitous tissue distribution. The remarkable or injection of growth hormone derived from human pitu-
nature of these diseases and the nature of the prion itaries (see DeArmond and Prusiner, 1996). Even more
protein conversion process as we currently understand striking have been a number of early-onset CJD cases
it are reviewed below. with atypical pathology recently reported from Great
Britain (Will et al., 1996 and see Figure 1), suggested to
have been transmitted by consumption of meat fromPrion DiseasesÐSpongiform Encephalopathies
cows suffering from ªmad cowº disease, a spongiformTransmitted by Inoculation, Cannibalism,
encephalopathy recently epidemic in British herds (seeGenetic Inheritance
Anderson et al., 1996, concerning progression of theThe first of these diseases to be recognized affected
epidemic). The recent reports of production of a clini-sheep, and its name, scrapie, derived from the observa-
cally and pathologically similar CJD in macaques bytion that affected animals rubbed against the fences of
intracerebral injection of brain homogenate from af-their pens to stay upright, presumably reflecting the
flicted cows (LasmeÂzas et al.,1996b), and of biochemicalmanifestation of ataxia. Transmissibility was acciden-
properties shared between the human cases and bovinetally but stunningly demonstrated in 1943 when a popu-
spongiform encephalopathy (BSE) (Collinge et al., 1996),lation of Scottish sheep was inoculated against a com-
suggest that BSE is transmissible to man.mon virus with a formalin extract of lymphoid tissue
unknowingly derived from an animal with scrapieÐafter
two years, nearly 10% of the flock developed scrapie Involvement of a Protein
The nature of the transmissible spongiform encepha-(Gordon, 1946). Some years later, a clinically and patho-
logically similar human disease, kuru, meaning ``trem- lopathies has been addressed by testing the ability of
infected brain homogenate to transmit disease toexper-bling,'' was identified in highlanders of New Guinea (Gaj-
dusek and Zigas, 1959; Hadlow, 1959). Here also, ataxia imental animals. In initial studies transferring to chim-
panzees and sheep, one or more years elapsed beforepredominated, proceeding to death usually within 9
months. In the brains of these patients, characteristic onset of clinical disease, but, in subsequent studies
with hamsters and mice, incubation periods as short as``plaque'' lesions, extracellular collections of protein-
aceous material, were observed (see Figure 1). Trans- 70±150 days were achieved, greatly facilitating experi-
mental work. Infectivity was found to be filterable, con-missibility of kuru was first demonstrated following intra-
cerebral inoculation of homogenate of kuru brain into sistent with the behavior of a virus, but, differing from
most viruses, formalin treatment did not completelychimpanzees (Gajdusek et al., 1966), but within the high-
lander population it was eventually surmised that trans- abolish infectivity (e.g., Gordon, 1946). In 1966, Alper
and coworkers made the additional surprising observa-mission was occurring by ritual cannibalism (Gajdusek,
1977). tion that the target size of the infectious material to UV
inactivation at 254 nm, was relatively small (Alper etThree other clinically or pathologically similar neuro-
degenerative diseases have been recognized in hu- al., 1966, 1967). Rather, infectivity proved to be more
sensitive to irradiation at 237 nm (Latarjet et al., 1970).mans, and for all of these, as with kuru, disease has been
observed to betransmissible to experimental animals by This action spectrum suggested the possibility that a
nucleic acid might not be involved. This led to a numberintracerebral inoculation. In 1936, Gerstmann, StraÈ us-
sler, and Scheinker described a condition with ataxia of hypotheses about the nature of the infectious agent,
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came from a fraction at the interface between 25% and
60% sucrose, where aggregates composed of amor-
phous material and flattened rods measuring 25 nm 3
100±200 nm were observed. The enriched activity was
inactivated by proteinase K, diethylpyrocarbonate, urea,
chaotropes, phenol, and SDS, but was not abolished by
nuclease treatments or UV irradiation. This behavior,
typical of a protein, gave rise to the name attached
by Prusiner and coworkers, ªprion,º for proteinaceous
infectious particle (Prusiner, 1982; see also Prusiner et
al., 1980).
The same workers identified a protein, designated
PrP, resistant to limited proteinase K digestion, that was
specifically present in infected hamster brain but not
in normal brain and exhibited a relative migration in
SDS±PAGE of 27±30 kDa (Bolton et al., 1982; Prusiner
et al., 1982). Whether this species was a byproduct of
infection, or was directly responsible, could not be im-
mediately distinguished, although the copurification ofFigure 1. Neuopathological Findings in Transmissible Spongiform
Encephalopathies proteinase K±resistant PrP 27±30 with infectivity offered
(Top Row) Plaque lesions in Creutzfeldt-Jacob disease (CJD) (first circumstantial evidence that it was involved with causa-
panel); the variant form of CJD (vCJD), recently shown to be trans- tion. Similarly, rod structures, first observed by Merz et
missible to primates from BSE-infected cattle (second panel); and al. (1981), were observed in the proteinase K±treated
Gerstmann-StrauÈ ssler Scheinker disease (GSS) (third panel). In the
extracts of infected brain and were found also to containfirst panel, the section is stained with PAS (periodic acid±Schiff
the PrP 27±30 core product. Preparations enriched forreaction) and shows a centrally located plaque lesion exhibiting the
these rods were shown to be highly infectious (Prusinerªspiked ballº appearance typical of a kuru plaque (from DeArmond
and Prusiner, 1995, with permission). In the second panel, the sec- et al., 1983; Diringer et al., 1983), although subsequent
tion is stained with PAS and shows a number of so-called ªflorid studies have shown that preparations devoid of visible
plaquesº typical of vCJD, in each case with a central plaque lesion structures can also be infectious. Coenrichment of PrP
surrounded by a daisy-like pattern of vacuoles (photomicrograph
27±30 and infectivity was observed in another setting,kindly supplied by J. Ironside, University of Edinburgh; see also Will
when immunoaffinity purification of detergent-lipid-sol-et al., 1996; and LasmeÂzas et al., 1996b). The third panel is a section
ubilized infected brain extract was carried out, showingimmunostained after hydrolytic autoclaving (Muramoto et al., 1992)
with anti-PrP antiserum, revealing the presence of PrP in the plaque several 1000-fold enrichment of both PrP 27±30 and
lesions of GSS. infectivity (Gabizon et al., 1988). This was consistent
(Middle Row) Spongiform changes typical of CJD. Section obtained with the notion that there is tight linkage between
from an affected transgenic mouse, carrying a chimeric mouse-
infectivity and the presence of some form of the PrPhuman-mouse transgene, that had been inoculated with brain ho-
protein. Nonetheless, despite years of effort, even in themogenate from a human sporadic CJD case (from DeArmond and
purest samples, the ratio of PrP molecules to infectiousPrusiner, 1995, with permission).
(Bottom Row) Histoblot analysis (Taraboulos et al., 1992) of brain units is z105. At such low infectivity, it is impossible
section from an individual with CJD and from an unaffected individ- to exclude the possibility that other components, or
ual. Staining is with anti-PrP antibody, showing extensive staining covalent modifications, are required for infectivity. How-
of PrP in the cortical mantle of the affected individual (from DeAr-
ever, highly-purified infectious material has been shownmond and Prusiner, 1995, with permission).
to contain less than one molecule of nucleic acid larger
than z100 nt for a particle-to-infectivity ratio near unity
ranging from a replicating polysaccharide to a nucleo- (Kellings et al., 1992). Thus, it seems likely that demon-
protein complex (for review, see Prusiner, 1982). Among stration of the protein only hypothesis will require the
these models was a prescient speculation, in which Grif- production of infectious particles in vitro from purified
fith suggested that ªconversionº of a protein from a PrP protein (that has a level of impurity of less than 1
normal energetically favored conformation to another part per infectious unit).
conformation, either spontaneously or by exogenous
introduction of the altered conformation, could explain Prion Protein Is Host EncodedÐ
these diseases (Griffith, 1967). A Conversion Process
The molecular natureof the infectious agent lay largely Purification of PrP 27±30 made it possible to obtain NH2-
untested for 15 years until Stanley Prusiner and cowork- terminal amino acid sequence (Prusiner et al., 1984) and,
ers achieved the biochemical enrichment of infectious ultimately, cDNA clones encoding PrP protein (Oesch
activity and showed its association with a specific pro- et al., 1985; Chesebro et al., 1985). PrP mRNA proved
tein. In early 1982, Prusiner and coworkers reported a to be the product of a single host cell nuclear gene.
1000-fold enrichment of scrapie infectivity from homog- The primary structure of PrP encoded by the gene of a
enate of infected brain, achieved through a series of normal animal was found to be identical to that encoded
steps including polyethylene glycol precipitation, micro- by a cDNA from a scrapie-infected animal (Basler et al.,
coccal nuclease digestion, limited proteinase K diges- 1986), and similar levels of mRNA were found in both
tion, and sucrose density gradient centrifugation (Prusi- settings (Chesebro et al., 1985; Oesch et al., 1985). Anti-
bodies generated against PrP 27±30 identified the PrPner et al., 1982; Prusiner, 1982). The highest activity
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protein not only in the brain of uninfected animals but 1996, and Figure 3). For example, many GSS kindreds,
including the original GSS family, harbor an amino acidalso in many visceral tissues as a 33±35 kDa glycosy-
lated species, termed PrPC. A protein of identical size substitution, P102L (Hsiao et al., 1989). In the case of
sporadic CJD, most patients are homozygous for a poly-was also observed in scrapie-infected brain extracts.
Strikingly, when limited proteinase K digestion was car- morphism at residue 129 (encoding either methionine
or valine), in the absence of any other mutation (Palmerried out, PrPC was completely degraded, whereas a frac-
tion of the protein in infected brain, termed PrPSc, was et al., 1991). Similarly, the recent early-onset CJD cases
potentially related to BSE exposure have affected indi-only partially cleaved, removing 66 NH2-terminal amino
acids to produce the species PrP 27±30. Thus, the PrP viduals homozygous for M129 (Will et al., 1996). Interest-
ingly, the corresponding mouse residue lies in the small,protein appears to have at least two distinct conforma-
tional states: a protease-sensitive one found ubiqui- two-stranded b sheet region of the recently determined
mouse PrP121±231 structure; this b sheet has beentously, and a protease-resistant one in the setting of
infection. Perhaps linked to such protease-resistant be- suggested to provide a nucleation point for conforma-
tional change during conversion (Riek et al., 1996; seehavior is the additional observation that, while PrPC is
a soluble protein, the PrPSc form is stubbornly insoluble, Figure 3B).
Two different genetic studies with mice have providedlocalizing in the amorphous aggregates in enriched frac-
tions from infected brain (e.g., Meyer et al., 1986). In any perhaps the strongest evidence arguing that infectious
particles are generated from the endogenous PrPC pro-case, the protease resistance of the PrPSc form has been
relied on to allow the detection of PrPSc in situ in both tein. In one, spontaneous prion disease was observed
in uninoculated transgenic mice expressing a mouseexperimental and clinical diagnosis. This is accom-
plished by pretreatment with proteinase K to remove PrP with a substitution homologous to that in GSS pa-
tients (Hsiao et al., 1990; Hsiao et al., 1994; Telling etPrPC, followed by guanidine treatment to expose epi-
topes of PrPSc for immunolocalization (Taraboulos et al., al., 1996a). Importantly, brain homogenates from these
mice can transfer prion disease when inoculated into1992, and see Figure 1 histoblot).
Given the same primary structure of PrPC and PrPSc, transgenic mice expressing low levels of the same mu-
tant PrP protein, that would not otherwise develop dis-the process whereby the normal state of PrP protein is
ªconvertedº to the infection-associated form seemed ease (Hsiao et al., 1994; Telling et al., 1996a). Thus, all
the components required to form infectious particleslikely to involve either posttranslational modification or
a change in conformation (e.g., Hope et al., 1986). Exten- appear to be present endogenously in the mice. More-
over, it appears that removal of the endogenous PrPsive biochemical characterization has failed to find any
covalent difference between the PrPC and PrPSc proteins gene in the latter study led toearlier onset of disease and
more severe pathology in the uninoculated transgenic(e.g., Stahl et al., 1993). By contrast, physical measure-
ments have demonstrated a dramatic conformational strain, reflecting that the presence of wild-type PrP
somehow interfered with disease production from thedifference in the PrP forms. For example, Fourier trans-
form infrared spectosocopy and circular dichroism indi- mutant transgene.
In a second avenue of study, a requirement for PrPCcate that the a-helical content of the PrPC form is z40%,
with little or no b sheet (Pan et al., 1993). By contrast, protein in generating infectivity was demonstrated di-
rectlyÐmice with a disruption in the endogenous PrPthe PrP 27±30 form contains 50% b sheet and only
z20% a helix (Caughey et al., 1991; Pan et al., 1993; gene (Prnp0/0) were both resistant to prion disease and
unable to generate new infectious particles (BuÈ eler et al.,Safar et al., 1993). The recently presented solution struc-
ture of a fragment of the mouse PrPC has allowed a 1993; Prusiner et al., 1993). A straightforward hypothesis
suggested by these observations is that endogenousdirect determination of secondary structure content of
this portion of PrPC (Riek et al., 1996). The agreement PrPC is converted to PrPSc conformation by the action
of an infectious form of the PrP molecule. However,with the FTIR study is excellent: out of 109 resolvable
residues in the PrP 121±232 species, 43 lie in a helix given the low specific activity of even the purest PrPSc
samples and the observation that under some circum-(40%), while only 8 residues lie in two short antiparallel
b strands (7%) (see Figure 3B). stances it appears that there can be both disease and
infectivity in the absence of protease-resistant material
(e.g., the GSS mice), it remains possible that the infec-
The Conversion ProcessÐEndogenous PrPC tious form of PrP is distinct from the protease-resistant
as the Target for ªInfectiousº PrPSc PrPSc form.
The notion that endogenous PrPC was involved with the
development of infection was first supported by the
observation that two strains of mice that had genetically Conversion Produces Host-Specific Prions and
Is Restricted by Interspecies ``Barriers''determined long versus short incubation times in the
face of prion exposure contained specific codon differ- The nature of the putative interaction between PrPC and
PrPSc that mediates conversion has been probed in vivoences present at two positions in the PrPC gene (Westa-
way et al., 1987). Subsequently, PrP genes in families in transgenic mouse experiments. Studies of the ªspe-
cies barrierº have been particularly revealing. The spe-with GSS, FFI, and CJD were found to encode either
specific amino acid substitutions or particular polymor- cies barrier is the phenomenon in which one species
tends to be resistant to infection by prion particles gen-phisms (including insertion/deletion of members of an
ªocta repeatº motif in the NH2-terminal portion) that erated in another. For example, higher primates were
thought to be resistant to infection from ungulates, e.g.,could be linked to development of disease (see Prusiner,
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cows, until the recent cases of a new variant of CJD,
termed vCJD, and the transmission of BSE tomacaques.
Moreover, mice are normally resistant to infection from
the widely used 263Kstrain of hamster prion but become
susceptible to this strain of hamster PrPSc (Scott et al.,
1989) following transgenic introduction of the hamster
PrP gene. Correspondingly, disruption of the endoge-
nous mouse gene and introduction of a hamster
transgene renders mice highly susceptible to hamster
prions and resistant to mouse prions (BuÈ eler et al., 1993;
Prusiner et al., 1993). This data is most easily reconciled
with a model in which there is a direct interaction be-
tween the infecting PrPSc and endogenous PrPC, and in
which that effective interaction is inhibited by differ-
Figure 2. Schematic Model for the Conversion of PrPC to PrPSc
ences in the PrP sequence. Between mouse and ham-
In the nucleation-polymerization model, conversion between the
ster, such a barrier must be mediated by one or more PrPC form (circles) and PrPSc form (squares) is inherently fast. How-
of the 16 differences (out of 254 residues) in the PrP ever, in the absence of an aggregate large enough to act as a stable
sequence (Scott et al., 1993). As would be predicted for nucleus, designated by the collectiveof PrPSc squares, the PrPC form
is thermodynamically favored. In the template assistance model, thea homologous conversion reaction in which new PrPSc
conversion of PrPC or an altered conformation, PrPInt, to PrPSc isis generated from the endogenous PrPC, when the spe-
extremely slow in the absence of PrPSc, but the conversion processcies of PrPSc in the brains of transgenic mice expressing
is effectively irreversible. The PrPSc is able to propagate itself by
the hamster PrPC was determined following challenge catalyzing the conversion of other PrPInt molecules to the PrPSc con-
with hamster prions, the hamster PrPSc protein was ob- formation. Additional unidentified factors, e.g., a molecular chaper-
served (Prusiner et al., 1990). Correspondingly, if the one, might also be involved in the conversion process (see text).
transgenic animals were inoculated with mouse prions,
mouse PrPSc was observed in the infected brain.
hamster, mouse, and the hamster-mouse chimeras wasThe location in the PrPC structure of the homologous
reproduced by the in vitro reaction (Kocisko et al., 1995).interaction with PrPSc was probed by producing
Moreover, there was preservation of ªstrainº specificitytransgenic mice bearing chimeric genes. When the
in vitro (discussed below), insofar as the distinct protein-midportion of the hamster sequence (codons 94±188),
ase K resistance patterns of PrPSc from two mink priondiffering at 5 residues from mouse, was substituted for
strains, presumably reflecting different PrPSc conforma-the corresponding region of mouse PrP, the transgenic
tions, were reproducible in the in vitro system (Bessenmice were observed to become susceptible to hamster
et al., 1995).prions, producing, as expected, chimeric PrPSc (Scott
et al., 1993 and see Figure 3A).
Models for the Conversion of PrPC to PrPSc
While the notion that a misfolded form of a protein could
catalyze the refolding of native molecules into a distinctConversion In Vitro
Despite considerable effort, it has not been possible to ªmisfoldedº conformation might seem radical, such a
process is by no means physically unreasonable. Twodemonstrate the production of infectious particles in
vitro. However, Caughey, Lansbury, and coworkers have distinct mechanisms have been proposed to account
for such behavior (Gajdusek, 1988; Prusiner, 1991; Jar-demonstrated the ability of PrPSc to convert PrPC in vitro
to a form that has proteolytic resistance resembling that rett and Lansbury, 1993; Cohen et al., 1994; Figure 2). In
one model, formation of PrPSc is a nucleation-dependentof PrPSc (Kocisko et al., 1994). In these studies, when
metabolically-labeled PrPC isolated by immunoprecipi- polymerization process. In the absence of a preexistent
aggregate, the conversion between PrPC and PrPSc istation was treated with 3 M guanidine HCl and then
diluted into a 50-fold excess of purified nonlabeled reversible, but PrPSc monomer is less stable than PrPC.
PrPSc aggregates, however, promote the conversion ofPrPSc, a portion was converted to a relatively protease-
resistant form, which generated a species resembling PrPC by binding to and stabilizing the otherwise unfa-
vored PrPSc conformation. The barrier to a stable conver-PrP 27±30 upon proteinase K digestion. Because only
a small amount of material was converted to a protease- sion process thus lies at the level of the initial nucleation
process, in which formation of low order aggregates isresistant form and because this occurred in the pres-
ence of an excess of PrPSc, biological assay of the na- not favored, since the free energy gained from intermo-
lecular interactions does not outweigh the entropic costscent protease-resistant material by measurement, for
example, of infectivity was not possible. Interestingly, of binding until a minimum size nucleus is attained. The
requirement that a nucleus be formed before conversionpretreatment of PrPSc with 3 M guanidine HCl, which
produced reversible unfolding of PrPSc, increased the is stable predicts certain characteristics of the aggrega-
tion process, including dependence on exceeding a crit-extent of conversion, suggesting that PrPSc itself may
also need to undergo a conformational change for con- ical protein concentration for the initial formation of ag-
gregates, and kinetics displaying a lag phase. The inversion to proceed, potentially accounting for the high
particle:infectivity ratio. Supporting the proposal that vitro conversion process appears to show such features
(Caughey et al., 1995), but whether a PrPSc nucleus isthe in vitro reaction faithfully reproduced that in vivo,
species specificity in the conversion reaction between already present is unclear from the design of the study.
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The relatively large size of the minimum stable nucleus kinetically inaccessible. Infectious prion disease could
would tend to make such a particle insoluble and could then result if PrPSc were able to accelerate the conver-
therefore account for the observation in the in vitro reac- sion of PrPC to PrPSc in a manner analogous to the cata-
tion that fractions containing higher-order PrPSc aggre- lyzed conversion between the I and N states of a-lytic
gates greater than 300 kDa in size could mediate the protease.
conversion to protease resistance while smaller-sized It is important to note that the nucleation and cata-
fractions could not. Infection would thus circumvent the lyzed conversion mechanisms are not mutually exclu-
slow step of nucleation by introducing a ªseedº that sive. For example, there could be a hybrid mechanism
initiates aggregation. by which the surface of an aggregate, which is initially
In a second proposed mechanism, the PrPSc form is formed by a nucleation process, catalyzes the confor-
inherently more stable than PrPC, but kinetically inacces- mational change of unconverted monomers. Indeed, in
sible (Prusiner, 1991; Figure 2). In this case, PrPSc could the case of flagella formation in vitro, kinetic studies
promote conversion by catalyzing the rearrangement of show a lag between the initial, reversible, binding, and
a molecule of PrPC, or of a partially destabilized interme- stable incorporation into the flagellum (Asakura, 1968).
diate, to the more stable PrPSc conformation (Figure 2). Moreover, NMR studies indicate that the NH2 and COOH
Infectivity would then rely on the ability of the PrPSc termini of flagellin, disordered in the monomers in solu-
molecule to bind to and catalyze the conversion of ex- tion, become ordered during the process of polymeriza-
isting intermediate molecules. By this template assis- tion (Aizawa et al., 1990). By analogy, it seems attractive
tance model, the genetically inherited diseases result to consider that PrPC could become converted in this
from mutations that increase the population of the un- manner, after an initial interaction with a PrPSc ag-
stable intermediate and/or enhance the rate at which gregate.
this form spontaneously converts to PrPSc. Other amyloid-forming diseases offer further opportu-
For bothof theproposed mechanisms, there are phys- nity for examining the mechanism of conformational re-
ical precedents. In the case of nucleation-polymeriza- arrangement. There are at least 15 human diseases in
tion, there is a resemblance to tubulin polymerization, which an accumulation of a specific protein can occur
crystal growth, sickle hemoglobin formation, viral capsid in characteristic insoluble fibers known as amyloid,
assembly, and bacterial flagellar polymerization. Flagel- which are typically 60±100 AÊ in diameter and exhibit
lar polymerization may be particularly instructive. The
characteristic birefringence when stained with the dye
soluble monomer unit, flagellin, becomes incorporated
Congo Red (for review, see Kelly, 1996). These amyloid
into the growing end of a flagellum (Asakura et al., 1964,
diseases result in a variety of different clinical presenta-
1966). Monomers in solution, even at nearly millimolar
tions, dependent on the sites of amyloid deposition, and
concentration,occupy a conformation unable tosponta-
include Alzheimer's disease, where neurodegeneration
neously nucleate, but if a seed of fragmented flagellum
occurs in association with deposition of the amyloid bis placed into the mixture, then polymerization rapidly
protein. Despite distinct folds in the native state, all ofensues. Interestingly, the polymerizing monomers can
the proteins involved in these diseases undergo confor-assume the conformation of even heterologous seed
mational alteration to a common structure in the amyloidmaterial, reflecting a ªtemplatingº behavior. It should be
fibril, a ªcross bº repeat structure in which b strandspointed out that while the foregoing ªaggregatesº adopt
are aligned perpendicular to the axis of the amyloida regular repeating structure, there is nothing in the
fiber. A recent fiber diffraction study with synchrotronphysics underlying a nucleation process that requires
radiation suggests that, in fact, it is b sheets that arethat the aggregates formed must have long-range order.
positioned perpendicular to the fiber axis and that theyThere is also precedent for the template-assisted, cat-
are arrayed as a continuous helix (Blake and Serpell,alyzed conversion mechanism, in which PrPC is a meta-
1996). As with prion disease, the other amyloidoses canstable conformation that does not spontaneously form
be initiated by inherited mutations in the respective cod-the more stable PrPSc at any appreciable rate. During
ing sequences, which apparently destabilize the nativethe past few years, a number of proteins have been
state of theseproteins, enabling them to rearrange to theobserved to occupy such conformations under kinetic
common conformation in amyloid. Such destabilizationcontrol, i.e., they are separated from their true free en-
has been elegantly demonstrated recently for two puri-ergy minima by a large barrier. These include influenza
fied amyloidogenic lysozyme variantsÐwhile they werehemagglutinin (Baker and Agard, 1994a), the serpin fam-
enzymatically active and crystallized in conformationsily of protease inhibitors (Sifers, 1995), and a number
nearly identical to wild-type, they exhibited little or noof proteases including subtilisin and a-lytic protease
protection from deuterium exchange when incubated in(Baker and Agard, 1994b). This last case of a-lytic prote-
solution at 378C, unlike wild type (Booth et al., 1997).ase is particularly revealing. Here, the interconversion
Lysozyme fibrils isolated from patient material, however,between a molten globule±like intermediate, I, and the
contained only the mutant lysozymesÐthe wild-typenative state, N, is extremely slow, allowing little or no
protein present in the heterozygous individuals was notconversion over the course of a month (reflecting a bar-
recruited. This underscores the major difference thatrier of z25 kcal/mole). Conversion, however, is dramati-
sets prion disease apart from otheramyloidoses, namelycally accelerated by binding of the naturally-occurring
that the aggregated form of PrP is also able to promotepropeptide region, in either cis or trans, allowing folding
the rearrangement of unmutated protein, thereby allow-to N to occur within minutes (the propeptide lowers
ing transmission of disease.the barrier by z14 kcal/mole). This behavior raises the
Recent studies with another amyloidosis, familial am-possibility that folding of PrP is also under kinetic con-
trol, with the PrPSc state thermodynamically favored but yloidotic polyneuropathy, provide further insight into an
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amyloidogenic conversion process (Kelly, 1996; Lai et distribution of CNS involvement, and even pattern of
proteolytic cleavage of PrPSc. These properties are re-al., 1996). The involved protein, transthyretin (TTR), is, in
native form, a homotetramer whose subunits are eight- tained even after repeated passage, as revealed by ex-
periments in isogenic mice (e.g., Fraser and Dickinson,stranded b sheet sandwiches. In vitro, upon exposure
to pH 4±5, TTR dissociates to monomers that undergo 1973; Bruce et al., 1976; Kimberlin et al., 1989; Carp and
Callahan, 1991; DeArmond et al., 1993). Strikingly, theretertiary structural rearrangement, and amyloid formation
ensues (Lai et al., 1996). As with prion conversion, con- appear to be conformational differences in PrPSc that
correlate with such behavior. A particularly good exam-trol of TTR amyloid formation could lie either at the step
of production of the amyloid aggregate or at the step of ple of this is the observation in transmissible mink en-
cephalopathy of two distinct presentations of faithfullymonomer rearrangement, invoking kinetic control. Both
mechanisms have been observed with TTR in vitro. In transmissible disease, hyper (HY) and drowsy (DY), that
describe the behavior of the affected animals, whichsupport of a nucleation step, fibril formation was ob-
served to exhibit a lag phase and to be accelerated are associated with characteristic incubation times and
locations of neuropathology. The two presentationsafter initiation by addition of amyloidogenic monomer.
In support of kinetic control, a greater amount of TTR were found to be associated also with characteristic
degrees of proteinase K susceptibility of PrPSc, with par-amyloid was formed at pH 4.4 during refolding from
denaturant than was observed starting with native pro- tial treatment producing different NH2 termini (Bessen
and Marsh, 1992, 1994). These different conformationstein, reflecting a kinetic barrier between the amyloido-
genic intermediate and the native tetramer. could represent either different tertiary structures or,
alternatively, different quaternary assemblies of theThus, for TTR, while both types of control have been
observed in vitro, it remains unclear what step is rate same fold. The latter case seems reminiscent of the
ability of many proteins to pack their native forms intolimiting in vivo. How high is the kinetic barrier to forma-
tion of the amyloidogenic form at physiological tempera- different crystal lattices, or of assembly of flagellar fila-
ments, in which addition of different seeds results in theture, pH, and ionic strength? In particular, without cata-
lyzed formation of the amyloidogenic intermediate, how formation of distinct structures. Such diversity can be
considerable, as in the case of the popular object ofcould there be enough accumulation of this intermediate
to form a stable nucleus that would promote efficient crystallization, hen egg lysozyme, shown to pack into
at least five different crystallographic space groups. Al-polymerization? Alternatively, if the barrier to production
of the intermediate is so high in vivo that a catalytic ternatively, it remains possible that there are modifica-
tions such as N-linked glycosylation that confer strain-event is required, what mediates such an event in the
absence of preexisting converted protein? Finally, given specific properties, although this modification does not
appear to be necessary for acquisition of a proteinasethe observation of seeding phenomena in vitro, why is
it that, unlike prions, TTR aggregates are apparently K±resistant PrPSc in a cultured cell system (Taraboulos
et al., 1990). Regardless of whether conformation ornoninfectious? Is this a property of the greater stability
of PrPSc? Or are the respective aggregates processed covalent differences are responsible, it seems possible
that strain-specific properties of incubation time anddifferently by the various organ systems involved? Con-
cerning such potentially different physiology, two obser- brain localization may reflect targeting of different forms
of PrPSc to specific CNS cells. These cells would thenvations seem worth noting. In the case of TTR, a mecha-
nism that clears TTR fibrils has recently been shown impart the same form to the newly-converted molecules
(Hecker et al., 1992; Weissmann et al., 1997).(Tan et al., 1995); and, in the case of prion disease, it
has been observed that, even following intracerebral While primary structural differences are not necessary
to produce different strains, an example of primary se-inoculation of mice with prions, there is early acquisition
of infectivity in the spleen, long preceding any appear- quence origin of strain properties in human prion dis-
ease has recently been reported (Telling et al., 1996b).ance of infectivity in the brain (Eklund et al., 1967;
Kimberlin and Walker, 1979; Weissmann et al., 1997). Human D178N FFI is associated with a proteinase
K±resistant PrPSc of 19 kDa after deglycosylation, whileConsistent with a primary replication step in the lympho-
reticular system that favors neuroinvasion, SCID mice both familial and sporadic CJD are associated with a
21 kDa species. Inoculation of the respective humanwere relatively resistant to CNS disease following intra-
peritoneal inoculation (only 6 affected out of 18 animals), brain homogenates into Prp-deleted mice containing a
chimeric mouse±human mouse (MHuM) PrP transgenecompared with immunocompetent littermates (13 of 14
animals) (LasmeÂ zas et al., 1996a; see also Kitamoto et produced disease associated with the respectively
sized PrPSc, indicating that the two distinct PrPSc speciesal., 1991). Presumably, those SCID animals that devel-
oped disease acquired CNS infection by direct neural can template a single primary MHuM PrP structure into
different conformations.spread, suggested in early studies to extend from pe-
The importance of studying the origin and nature ofripheral nervous system to spinal cord to brain (e.g.,
strain differences has been emphasized recently by theKimberlin and Walker, 1979).
reports of a number of cases of vCJD that appear to be
linked to BSE epidemic in British cattle (Will et al., 1996).
Prion ªStrainsº: Multiple Distinct PrPSc Conformations Despite the small numberof cases, a number of observa-
Perhaps one of the most difficult phenomena to fathom tions suggests that vCJD represents a novel disease
in light of a protein only hypothesis is the existence distinct from sporadic CJD. First, vCJD has a distinct
of distinct prion ªstrains,º reflecting observations that pathology characterized by abundant ªflorid plaques,º
infectious material from different sources can produce decorated by a daisy-like pattern of vacuolation (Figure
1). Second, there is a far younger age of onset than indistinct and reproducible patterns of incubation time,
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sporadic CJD. The notion that vCJD could be transmit- and Rose, 1992; Smart et al., 1995). Supporting a role
of such a compartment, treatment of the cultured cellted from cattle to primates was supported by the obser-
vation that intracerebral inoculation of BSE-infected system with the inhibitor of cholesterol biosynthesis,
lovastatin, blocked the conversion process, but it wasbrain extract into Macaque monkeys produced disease
and pathology resembling that in the vCJD patients (Las- unclear whether this effect was mediated by failure of
PrPC to reach the cell surface or by disruption of themeÂ zas et al., 1996b). This raised the possibility that vCJD
was a newly-identified strain of prion that was less re- DIGS where conversion might take place (Taraboulos
et al., 1995). Additional uncertainty is cast by the obser-stricted by the species barrier. This was supported re-
cently by studies examining the pattern of proteinase vation that absence of the GPI anchor from a truncated
PrP inhibited but did not prevent production of the pro-K±resistant PrPSc species from the vCJD patients, in
particular comparing di-, mono-, and non-glycosylated teinase K±resistant PrPSc species in the cultured cells
(Rogers et al., 1993).species with those from brain homogenates of patients
with sporadic or iatrogenic CJD, and homogenates from Whatever the specific compartments involved, it
seems clear that PrPC reaches the cell surface and thatBSE-infected animals including cats and macaque
(Collinge et al., 1996). vCJD was observed to share a this localization may make it an easily accessible target
for exogenous PrPSc, although it seems equallyclear thatcommon pattern with BSE-infected animals, distinct
from that of sporadic or acquired CJD. The proteinase PrPSc presented from outside the cell could internalize
down the same pathway as PrPC and mediate conver-K±resistant diglycosylated species was particularly
prominent, raising questions of whether this form of PrPC sion internally. Whichever the site, the notion that con-
version could take place in a specific membranous com-is more susceptible to BSE-mediated conformational
change or whether a population of cells preferentially partment containing a specific subset of proteins has
potential for reconstitution studies. If such a PrPC-con-producing diglycosylated PrP may be more readily tar-
geted by BSE (Aguzzi and Weissmann, 1996). taining compartment is isolable as a low density Triton-
insoluble membrane fraction, it should be possible to
test for conversion with the isolated fraction, potentially
Conversion Process In Vivo allowing the delimiting of components that are critical
The failure thus far to demonstrate conversion of PrPC to conversion.
to an infectious form in vitro underscores the need for Recent transgenic studies on the susceptibility of
a better understanding of the factors present in vivo mice expressing chimeric human-mouse PrPC suggest
that facilitate this process. Studies of the biosynthesis that at least one host factor other than PrPC, tentatively
and processing of the PrP proteins in cultured cells termed factor X, might be involved in susceptibility to
have provided important clues to where the conversion infection (Telling et al., 1995). Conceivably, factor X
process might take place (Butler et al., 1988; Caughey could be a molecular chaperone that binds to PrPC and
et al., 1989). These studies indicate that the protein assists in altering its conformation. A precedent for
normally traverses the secretory pathway to reach the chaperone involvement in a conversion process comes
cell surface where it faces the external environment, from recent studies in yeast, where the cytosolically
anchored to the plasma membrane via a GPI anchor localized product of the SUP35 gene, involved with
attached at its COOH terminus (Stahl et al, 1987). In translational termination, can be converted to a biologi-
reaching this destination, an NH2-terminal secretory sig- cally inactive aggregated molecule, conferring a pheno-
nal peptide of 22 amino acids is cleaved, and 23 COOH- type of nonsense suppression (PSI1) (Chernoff et al.,
terminal residues are also processed during addition of 1995; Patino et al., 1996; Paushkin et al., 1996; see also
the anchor to S231. In scrapie-infected cultured cells, Masison and Wickner, 1995). The SUP35 aggregates
PrPC was observed to undergo turnover with a t1/2 5 z6 appear to act as a nucleus, promoting the aggregation
hr (Caughey et al., 1989), but slow conversion of a small of newly synthesized SUP35 protein, allowing propaga-
fraction (z5%) of newly synthesized, metabolically- tion of thePSI1 state ina manner analogous to the PrPC-
labeled PrPC was observed (t1/2 5 z5±15 hr), to a form to-PrPSc conversion process. Strikingly, maintenance of
that exhibited the same proteinase K resistance as PrPSc the PSI1 state was found to depend on the molecular
and that accumulated (Borchelt et al., 1990; Caughey chaperone, Hsp104, a large homohexameric single ring
and Raymond, 1991). structure with two ATP-binding sites in each of its sub-
Additional studies in the cultured cell system showed units, which has previously been shown to have a pro-
that conversion to PrPSc could be blocked by addition pensity to dissociate protein aggregates produced by
of exogenous PI-specific phospholipase C or by prote- heat shock (Parsell et al., 1994). Remarkably, either dele-
ases, suggesting that PrPC undergoes conversion either tion of Hsp104 or its overexpression resulted in concor-
at the cell surface or after internalization from the cell dant disappearance of the SUP35 aggregates and loss
surface into the endocytic pathway (Caughey and Ray- of the PSI1 state. In the case of PrP conversion, a
mond, 1991; Borchelt et al., 1992). In support of a re- general chaperone component like Hsp104 has not so
quirement for internalization, low temperature incuba- far been identified in the cellular locations where conver-
tion (188C), which retards endocytosis, also blocked sion appears to occur.
production of PrPSc (Borchelt et al., 1992). Additional
efforts to refine the localization have noted that
GPI-anchored proteins localize at the cell surface in Structural Studies of PrPC
Ultimately, an understanding of the conversion processcholesterol-rich plasma membrane invaginations that
are Triton X-100 insoluble, known as DIGS (detergent- will likely require knowledge of the three-dimensional
structure of the different PrP conformations. A majorinsoluble glycosphingolipid-enriched membranes) (Brown
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Figure 3. Structure of Prion Protein
(A) Primary structure of mature human PrP. The sequence of the mature protein, residues 23±231, after proteolytic processing of the NH2-
terminal secretory signal and the COOH-terminal region beyond the GPI anchor site, is shown. Mutations involved with inherited human
disease are indicated in red, above the line, and naturally occurring polymorphisms are shown as numerator/denominator on the line, in
purple. The asterisk indicates a mutation producing a stop codon at amino acid 145. Residues implicated in species barriers are also shown,
between human and mouse (backlit in blue), and between mouse and hamster (backlit in yellow). Secondary structure of corresponding region
123±231 of mouse PrP, determined from the NMR structure (Riek et al., 1996), is shown above the primary sequence, with b strands represented
by arrows and a helices by cylinders.
(B) Structure of mouse prion protein domain PrP121±231. Two opposite faces are shown of the mouse PrP121±231 structure recently determined
by NMR (taken from Riek et al., 1996, with permission). Ribbon diagrams are shown in the two left panels, displaying the three a helices and
the short antiparallel two-stranded b sheet. In the top left panel, green indicates well resolved loop structure, whereas purple indicates poorly
resolved loop structure. A disulfide bond is shown in white. In the bottom left panel, side chains associated with inherited prion disease are
shown in red, and residues that may be involved in the species barrier between mouse and human are shown in blue (Q168 side chain is not
shown). (Note that side chain numbering corresponds to the human sequence shown in [A]). Two solvent-accessible glycosylation sites are
also shown in green and the disulfide bond in yellow. Electrostatic potential plots are shown in the two right panels, displaying positive charge
as blue and negative charge as red. The aspect of the molecule shown in the top panel has been suggested to possibly face a membrane,
whereas the opposite, negatively-charged aspect (lower panels) may present a binding surface for an as yet unidentified ligand (see text).
advance in this direction is the recent NMR structure conformational transition to the b sheet±rich PrPSc form,
that could presumably incorporate neighboring loops.determination of a mouse PrP molecule containing resi-
dues 121±231 (Riek et al., 1996 and see Figure 3). This Interestingly, the methionine/valine polymorphism af-
fecting disposition to CJD maps into one of thesepolypeptide was stable and soluble when programmed
in E.coli for localization to the periplasm, and it com- strands. The observation that heterozygosity for Met/
Val at this position is protective (Palmer et al., 1991)prises a significant portion of a minimal region of PrP,
residues 80±231, that can mediate disease (Fischer et leaves one to wonder whether these strands might also
be involved in intermolecular contacts involved in eitheral., 1996; see also Muramoto et al., 1996). Given its
solubility at millimolar concentration, and a high a helix/ the conversion process or in aggregation of PrPSc.
Analysis of the surface properties of the PrP121±231low b sheet composition, it seems probable that it occu-
pies a conformation similar to that in intact PrPC. molecule reveal two disparate faces (Figure 3B). One is
overall electrostatically positive but contains intermin-The secondary structure of PrP121±231 features three
a helices and two short antiparallel b strands (Figure gled hydrophobic patches, suggesting that it could face
the cell membrane. The opposite face, by contrast, is3B). Glockshuber, Wuthrich, and coworkers speculate
that this latter feature could be a ªnucleation siteº for a electrostatically negative, containing the two sites of
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glycosylation. Riek et al. suggest that it could be a site of classic prion disease. Conversely, can production of
PrPSc alone produce disease? An elegant study ofof binding of an as yet unidentified ligand. (Could this
be PrPC itself, on another cell, for example?) In addition, Aguzzi, Weissmann, and coworkers has recently ad-
dressed this question (Brandner et al., 1996a). They en-this surface bears at one edge containing the first a
helix, a region suggested to act as an accessible binding grafted brain tissue from a PrPC-expressing normal
mouse into a null animal and then inoculated with mousesite for PrPSc. This region contains 5 of 14 residues impli-
cated by chimeric transgenic studies to be important prions. They observed the characteristic pathology of
prion disease precisely within the engrafted tissue, butfor either the human-mouse or hamster-mouse species
barrier (Figure 3A and 3B). Three of the remaining resi- not within the null tissue. Nevertheless, PrPSc produced
within the diseased tissue migrated into the neighboringdues involved in the species barrier lie at the opposite
edge of the molecule, located in a loop region between null tissue. Thus, PrPSc by itself was insufficient to pro-
duce diseaseÐi.e., simple exposure to exogenous PrPScthe second b strand and the second a helix (only 166
is shown in Figure 3B). The remaining five residues form is insufficient for cytotoxicity. Rather, PrPSc may be toxic
only when formed within the cell, or when presenteda third putative PrPSc binding site located between resi-
dues 90 and 122, a region not present in the structure. from outside to a cell already expressing PrPC, so that
conversion ensues either at the cell surface or in anInterestingly, the sites of the species barrier and of
disposing human mutations appear to be, so far, mutu- internalized compartment. Furthermore, Brandner and
colleagues have also shown that propagation of infec-ally exclusive. Whereas the region including a helix 1
appears to be a determinant of the species barrier, hu- tion across neural pathways in the CNS requires the
presence of PrPC along the pathway (Brandner et al.,man mutations disposing to disease map to the region
of the two other a helices, with three mapping into the 1996b), insofar as grafts in null animals did not become
infected following intraocular inoculation. Thus, in allhydrophobic core and three to the electrostatically neg-
ative surface. Such mutations could, correspondingly, cases, it appears that the presence of PrPC is required
for pathogenesis.either destabilize the structure or affect ligand binding.
With structural information of this sort now in hand,
it will bepossible to carry out a host of structure-function Perspective
studies relating the regions of the species barrier and An enormous body of data reveals the central role of
human mutations to the conversion process. For exam- the PrP protein in a group of related transmissible neuro-
ple, it should be possible to assess the relative impor- degenerative diseases. These data demonstrate that
tance of the three structural regions implicated in the PrP protein is required for the disease process and that
species barrier. In addition, designed mutants with ei- the conformational conversion of the PrP protein from
ther decreased or increased PrPC stability, measured its normal soluble a-helical conformation to an insoluble
in vitro with purified recombinant protein, will make it b sheet state is intimately tied to the generation of dis-
possible to test directly whether destabilization of the ease and infectivity. Much about the conversionprocess
native PrPC structure facilitates conversion in vivo. Fi- remains unclear. In particular, is introduction of the PrPSc
nally, antibodies generated against peptides that are protein alone sufficient for infection in the presence of
buried in the native PrPC structure may potentially pro- PrPC? What is the nature of the conformational change?
vide reagents for specifically detecting the PrPSc form. Given the ubiquitous distribution of PrPC, why is prion
While PrPC is at last yielding to structural analysis, by pathology restricted to the central nervous system?
contrast, in the absence of protocols for solubilizing What determines the species barrier? In addition to fur-
PrPSc, structural information on the converted form may ther resolving a fascinating biological process, the expo-
require nonsolution techniques such as solid state NMR sure of both cows and people to BSE underscores a
(e.g., Heller et al., 1996). need to answer these questions.
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